首页> Oncotarget> The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status.

The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status.

导出 OA

翻译打印收藏纠错

第一作者： Giuseppe,Bronte

第一单位： Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.

作者： Giuseppe,Bronte ^[1] ; Tindara,Franchina ^[2] ; Massimiliano,Alù ^[3] ; Giovanni,Sortino ^[1] ; Claudia,Celesia ^[1] ; Francesco,Passiglia ^[1] ; Giuseppina,Savio ^[3] ; Agata,Laudani ^[3] ; Alessandro,Russo ^[2] ; Antonio,Picone ^[2] ; Sergio,Rizzo ^[1] ; Michele,De Tursi ^[4] ; Elisabetta,Gambale ^[4] ; Viviana,Bazan ^[1] ; Clara,Natoli ^[4] ; Livio,Blasi ^[3] ; Vincenzo,Adamo ^[2] ; Antonio,Russo ^[1]

作者单位： Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy. ^[1] Medical Oncology Unit-AOOR Papardo-Piemonte, Messina and Department of Human Pathology, University of Messina, Messina, Italy. ^[2] Medical Oncology Unit, A.R.N.A.S. Civico, Palermo, Italy. ^[3] Department of Medical, Oral and Biotechnological Sciences, University "G. D'Annunzio", Chieti, Italy. ^[4]

关键词 EGFR chemotherapy non-small-cell lung cancer tyrosine kinase inhibitor